News Release

Shareholder Tools

AmerisourceBergen Announces Date and Time for First Quarter Fiscal 2018 Earnings Release

VALLEY FORGE, Pa.--(BUSINESS WIRE)--Jan. 8, 2018--
AmerisourceBergen Corporation (NYSE:ABC) today announced that it plans
to release its results for the First Quarter Fiscal 2018 on Tuesday,
February 6, 2018 prior to the opening of trading on the New York Stock
Exchange. The Company will host a conference call to discuss the results
at 8:30 a.m. ET on February 6, 2018.

The dial-in number for the live call will be (612) 288-0337. No access
code is required. The live call will also be webcast via the Company’s
website at investor.amerisourcebergen.com.
Users are encouraged to log on to the webcast approximately 10 minutes
in advance of the scheduled start time of the call.

Replays of the call will be made available via telephone and webcast. A
replay of the webcast will be posted on investor.amerisourcebergen.com
approximately two hours after the completion of the call and will remain
available for 30 days. The telephone replay will also be available
approximately two hours after the completion of the call and will remain
available for seven days. To access the telephone replay from within the
U.S., dial (800) 475-6701. From outside the U.S., dial (320) 365-3844.
The access code for the replay is 442500.

About AmerisourceBergen

AmerisourceBergen provides pharmaceutical products, value-driving
services and business solutions that improve access to care. Tens of
thousands of healthcare providers, veterinary practices and livestock
producers trust us as their partner in the pharmaceutical supply chain.
Global manufacturers depend on us for services that drive commercial
success for their products. Through our daily work—and powered by our
20,000 associates—we are united in our responsibility to create
healthier futures. AmerisourceBergen is ranked #11 on the Fortune 500,
with more than $150 billion in annual revenue. The company is
headquartered in Valley Forge, Pa. and has a presence in 50+ countries.
Learn more at investor.amerisourcebergen.com.

Certain of the statements contained in this press release are
“forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. Words such as “expect,” “likely,” “outlook,” “forecast,” “would,”
“could,” “should,” “can,” “will,” “project,” “intend,” “plan,”
“continue,” “sustain,” “synergy,” “on track,” “believe,” “seek,”
“estimate,” “anticipate,” “may,” “possible,” “assume,” variations of
such words, and similar expressions are intended to identify such
forward-looking statements. These statements are based on management’s
current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance
and are based on assumptions that could prove incorrect or could cause
actual results to vary materially from those indicated. Among the
factors that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: unfavorable trends
in brand and generic pharmaceutical pricing, including in rate or
frequency of price inflation or deflation; competition and industry
consolidation of both customers and suppliers resulting in increasing
pressure to reduce prices for our products and services; changes in
pharmaceutical market growth rates; changes in the United States
healthcare and regulatory environment, including changes that could
impact prescription drug reimbursement under Medicare and Medicaid;
increasing governmental regulations regarding the pharmaceutical supply
channel and pharmaceutical compounding; declining reimbursement rates
for pharmaceuticals; federal and state government enforcement
initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances; increased public
concern over the abuse of opioid medications; prosecution or suit by
federal, state and other governmental entities of alleged violations of
laws and regulations regarding controlled substances, and any related
disputes, including shareholder derivative lawsuits; increased federal
scrutiny and litigation, including qui tam litigation, for alleged
violations of laws and regulations governing the marketing, sale,
purchase and/or dispensing of pharmaceutical products or services, and
associated reserves and costs, including the reserve recorded in
connection with the proceedings with the United States Attorney’s Office
for the Eastern District of New York; material adverse resolution of
pending legal proceedings; the retention of key customer or supplier
relationships under less favorable economics or the adverse resolution
of any contract or other dispute with customers or suppliers; changes to
customer or supplier payment terms; risks associated with the strategic,
long-term relationship between Walgreens Boots Alliance, Inc. and the
Company, including principally with respect to the pharmaceutical
distribution agreement and/or the global generic purchasing services
arrangement; changes in tax laws or legislative initiatives that could
adversely affect the Company’s tax positions and/or the Company’s tax
liabilities or adverse resolution of challenges to the Company’s tax
positions; regulatory action in connection with the production, labeling
or packaging of products compounded by our compounded sterile
preparations (CSP) business; failure to realize the expected benefits
from our reorganization and other business process initiatives; managing
foreign expansion, including non-compliance with the U.S. Foreign
Corrupt Practices Act, anti-bribery laws and economic sanctions and
import laws and regulations; declining economic conditions in the United
States and abroad; financial market volatility and disruption;
substantial defaults in payment, material reduction in purchases by or
the loss, bankruptcy or insolvency of a major customer; the loss,
bankruptcy or insolvency of a major supplier; changes to the customer or
supplier mix; malfunction, failure or breach of sophisticated
information systems to operate as designed; risks generally associated
with data privacy regulation and the international transfer of personal
data; natural disasters or other unexpected events that affect the
Company’s operations; the impairment of goodwill or other intangible
assets, resulting in a charge to earnings; the acquisition of businesses
that do not perform as expected, or that are difficult to integrate or
control, including the integration of H. D. Smith and PharMEDium, or the
inability to capture all of the anticipated synergies related thereto or
to capture the anticipated synergies within the expected time period;
the effects of disruption from the transactions on the respective
businesses of the Company and H. D. Smith and the fact that the
transactions may make it more difficult to establish or maintain
relationships with employees, suppliers, customers and other business
partners; the disruption of the Company’s cash flow and ability to
return value to its stockholders in accordance with its past practices;
interest rate and foreign currency exchange rate fluctuations; and other
economic, business, competitive, legal, tax, regulatory and/or
operational factors affecting the Company’s business generally. Certain
additional factors that management believes could cause actual outcomes
and results to differ materially from those described in forward-looking
statements are set forth (i) in Item 1A (Risk Factors) in the Company’s
Annual Report on Form 10-K for the fiscal year ended September 30, 2017
and elsewhere in that report and (ii) in other reports filed by the
Company pursuant to the Securities Exchange Act.

Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel..